Tag Archives: Matt Miksic

Abbott Labs (ABT) Gets a Buy Rating from Credit Suisse

Credit Suisse analyst Matt Miksic reiterated a Buy rating on Abbott Labs (ABT – Research Report) yesterday and set a price target of $106.00. The company’s shares closed last Friday at $91.09. According to TipRanks.com, Miksic is a 5-star analyst

NuVasive (NUVA) Receives a Buy from Credit Suisse

Credit Suisse analyst Matt Miksic maintained a Buy rating on NuVasive (NUVA – Research Report) today and set a price target of $74.00. The company’s shares closed last Thursday at $58.29. According to TipRanks.com, Miksic is a 5-star analyst with

Credit Suisse Believes Johnson & Johnson (NYSE: JNJ) Won’t Stop Here

In a report released today, Matt Miksic from Credit Suisse reiterated a Buy rating on Johnson & Johnson (JNJ – Research Report), with a price target of $161.00. The company’s shares closed last Tuesday at $152.33, close to its 52-week

Edwards Lifesciences (EW) Receives a Buy from Credit Suisse

Credit Suisse analyst Matt Miksic maintained a Buy rating on Edwards Lifesciences (EW – Research Report) today and set a price target of $262.00. The company’s shares closed last Friday at $223.39. According to TipRanks.com, Miksic is a 5-star analyst

Credit Suisse Believes Abbott Labs (NYSE: ABT) Won’t Stop Here

In a report released today, Matt Miksic from Credit Suisse reiterated a Buy rating on Abbott Labs (ABT – Research Report), with a price target of $106.00. The company’s shares closed last Friday at $95.65, close to its 52-week high

Analysts Offer Insights on Financial Companies: Organogenesis Holdings (NASDAQ: ORGO) and OneMain Holdings (NYSE: OMF)

There’s a lot to be optimistic about in the Financial sector as 2 analysts just weighed in on Organogenesis Holdings (ORGO – Research Report) and OneMain Holdings (OMF – Research Report) with bullish sentiments. Organogenesis Holdings (ORGO) Credit Suisse analyst